Internal Medicine, Infectious Disease · Milwaukee, WI
NPI
1619181591
Since 2007
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
9200 W Wisconsin Ave, Division of Infectious Diseases
Milwaukee, WI, 53226
Phone (414) 805-6444
Groups this clinician bills Medicare through
Medicare paid, 2024
$35K
537 services
Medicare patients, 2024
191
Average age 74
Drug cost, 2024
$854K
1,238 prescriptions
Company payments, 2024
$0
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Carlos E Figueroa Castro was code 99214 (office e&m - established), 84 times for 50 patients. In total Carlos E Figueroa Castro billed 537 services in 15 codes, and Medicare paid $35K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-10-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 84 | 50 | $84.85 | $7,128 |
| 99214 Office E&M - Established | Facility | 62 | 32 | $65.21 | $4,043 |
| 99232 Hospital E&M - Subsequent | Facility | 56 | 34 | $59.41 | $3,327 |
| 99222 Hospital E&M - Initial | Facility | 43 | 39 | $97.59 | $4,196 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 42 | 28 | $12.63 | $530 |
| 99221 Hospital E&M - Initial | Facility | 42 | 41 | $57.39 | $2,410 |
| 99213 Office E&M - Established | Facility | 39 | 24 | $44.09 | $1,719 |
| 99213 Office E&M - Established | Office | 34 | 25 | $65.65 | $2,232 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 33 | 21 | $12.33 | $407 |
| 99233 Hospital E&M - Subsequent | Facility | 31 | 16 | $83.79 | $2,598 |
| 99204 Office E&M - New | Facility | 15 | 15 | $98.27 | $1,474 |
By year: 2022 $41K for 544 services; 2023 $42K for 541 services; 2024 $35K for 537 services.
Medicare prescription drug claims, 2024
In 2024, the drug Carlos E Figueroa Castro prescribed most often to Medicare patients was Azithromycin, with 136 prescriptions and refills. In total Carlos E Figueroa Castro wrote 1,238 Medicare prescriptions that cost $854K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Azithromycin Generic | 136 | 180 | 27 | $2,160 |
| Ethambutol Hcl Generic | 125 | 159 | 21 | $6,094 |
| Rifampin Generic | 100 | 130 | 21 | $5,630 |
| Doxycycline Hyclate Generic | 85 | 131 | 30 | $3,825 |
| Cefdinir Generic | 61 | 75 | 11 | $4,022 |
| Amoxicillin Generic | 54 | 99 | 17 | $307 |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | 46 | 56 | 14 | $1,062 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 39 | 60 | Under 11 | $1,009 |
| Levofloxacin Generic | 38 | 46 | 15 | $814 |
| Cefadroxil Generic | 36 | 40 | Under 11 | $2,923 |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 34 | 34 | Under 11 | $123K |
| Cephalexin Generic | 33 | 67 | 11 | $1,077 |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 29 | 29 | Under 11 | $120K |
| Amikacin Sulfate Generic | 27 | 27 | Under 11 | $1,460 |
| Fluconazole Generic | 24 | 32 | 11 | $897 |
Brand drugs: 173 claims; generic drugs: 1,065 claims.
Money and other things of value reported by the companies
In 2024, drug and medical device companies paid Carlos E Figueroa Castro $0 (- in general payments such as food, travel and fees) from 1 company.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.